The 291 references in paper J.M. López-Novoa, A.B. Rodríguez-Peña, A. Ortiz, C. Martínez-Salgado, F.J. López Hernández, Дж. М. Лопес-Новойя, А. Б. Родригес-Пена, А. Ортис, К. Мартинес-Салдаго, Ф. Дж. Лопес Эрнандес (2013) “ЭТИОПАТОЛОГИЯ ХРОНИЧЕСКОЙ ТУБУЛЯРНОЙ, ГЛОМЕРУЛЯРНОЙ И РЕНОВАСКУЛЯРНОЙ НЕФРОПАТИЙ: КЛИНИЧЕСКИЕ АСПЕКТЫ // ETIOPATHOLOGY OF CHRONIC TUBULAR, GLOMERULAR AND RENOVASCULAR NEPHROPATHIES: CLINICAL IMPLICATIONS” / spz:neicon:nefr:y:2013:i:2:p:9-38

1
Mitch WE, Walser M, Buffington GA et al. A simple method of stimating progression of chronic renal failure. Lancet 1976;2:1326–1328
(check this in PDF content)
2
Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Inves 2006;116:288–296
(check this in PDF content)
3
Chin C. Renal failure: Pharmacologic issues. Pharmacy Practice 2002, 1–8
(check this in PDF content)
4
Levey AS, Coresh J, Balk E, et al. National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137–147
(check this in PDF content)
5
Snively CS, Gutierrez C. Chronic kidney disease: Prevention and treatment of chronic complications. American Family Physician 2004;70:1921–1928
(check this in PDF content)
6
Snyder S, Pendergraph B. Detection and evaluation of chronic kidney disease. American Family Physician 2005;72:1723– 1732
(check this in PDF content)
7
Feig DI. Uric acid: a novel mediator and marker of risk in chronic kidney disease? Curr Opin Nephrol Hypertens. 2009;18:526–530
(check this in PDF content)
8
Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010;5:1388–1393
(check this in PDF content)
9
Bellomo G, Venanzi S, Verdura C, et al. Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis 2010;56: 264–272
(check this in PDF content)
10
Brenner BM. Nephron adaptation to renal injury or ablation. Am J Physiol 1985;249 (3):F324–F337
(check this in PDF content)
11
Molitch ME, DeFronzo RA, Franz MJ, et al. American Diabetes Association. Nephropathy in diabetes. Diabetes Care 2004;7 [Suppl 1]:S79–S83
(check this in PDF content)
12
U.S. Renal Data System, USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2009
(check this in PDF content)
13
Brosnahan G, Fraer M. Chronic kidney disease: whom to screen and how to treat, part 1: definition, epidemiology, and laboratory testing. South Med J 2010;103:140–146
(check this in PDF content)
14
Stengel B, Tarver-Carr ME, Powe NR, et al. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology 2003;14:479–487
(check this in PDF content)
15
Hsu CY, Mc Culloch ChE, Iribarren C, et al. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006;144:21–28
(check this in PDF content)
16
Ejerblad E, Foerd M, Lindblad P, et al. Obesity and risk for chronic renal failure. J Am Soc Nephrol 2006;17:1695–1702
(check this in PDF content)
17
Ritz E. Metabolic syndrome and kidney disease. Blood Purif 2008;26:59–62
(check this in PDF content)
18
Hall JE, Crook ED, Jones DW, et al. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Medical Sciences 2002;324:127–137
(check this in PDF content)
19
Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004;140:167–174
(check this in PDF content)
20
Ting SM, Nair H, Ching I, et al. Overweight, obesity and chronic kidney disease. Nephron Clin Pract 2009;112:c121–127
(check this in PDF content)
21
Faronato PP, Maioli M, Tonolo G, et al. Clusterin of albumin excretion rate abnormalities in Caucassian patients with NIDDM. The Italian NIDDM nephropathy study group. Diabetologia 1997;40:816–823
(check this in PDF content)
22
Satko SG, Freedman BI. The importance of family history on the development of renal disease. Curr Opin Nephrol Hypertens 2004;13:337–341
(check this in PDF content)
23
Gohda T, Tanimoto M, Watanabe-Yamada K, et al. Genetic susceptibility to type 2 diabetic nephropathy in human and animal models. Nephrology (Carlton) 2005;10 [Suppl]:S22–S25.
(check this in PDF content)
24
Satko SG, Freedman BI, Moossavi S. Genetic factors in end-stage renal disease. Kidney Int 2005;94 [Suppl]: S46–S49
(check this in PDF content)
25
Kao WH, Klag MJ, Meoni LA, et al. Family Investigation of Nephropathy and Diabetes Research Group. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008;40:1185–1192
(check this in PDF content)
26
Freedman BI, Hicks PJ, Bostrom MA, et al. Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int 2009;75:736–745
(check this in PDF content)
27
Divers J, Freedman BI. Susceptibility genes in common complex kidney disease. Curr Opin Nephrol Hypertens 2010;19:79–84
(check this in PDF content)
28
Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010;329:841–845
(check this in PDF content)
29
Tsukaguchi H, Sudhakar A, Le TC, et al .NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele. J Clin Invest 2002;110:1659–1666
(check this in PDF content)
30
Franceschini N, North KE, Kopp JB, et al. NPHS2 gene, nephrotic syndrome and focal segmental glomerulosclerosis: a HuGE review. Genet Med 2006;8:63–75
(check this in PDF content)
31
Brown EJ, Schlöndorff JS, Becker DJ, et al. Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. Nat Genet 2010;42:72–76
(check this in PDF content)
32
Mukerji N, Damodaran TV, Winn MP. TRPC6 and FSGS: the latest TRP channelopathy. Biochim Biophys Acta 2007;1772:859–868
(check this in PDF content)
33
Korstanje R, DiPetrillo K. Unraveling the genetics of chronic kidney disease using animal models. Am J Physiol Renal Physiol 2004;287:F347–352
(check this in PDF content)
34
Imperatore G, Hanson RL, Pettitt DJ, et al. Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Pima Diabetes Genes Group. Diabetes 1998;47:821–830
(check this in PDF content)
35
DeWan AT, Arnett DK, Atwood LD, et al. A genome scan for renal function among hypertensives: the HyperGEN study. Am J Hum Genet 2001;68:136–144
(check this in PDF content)
36
Perez-Luque E, Malacara JM, Olivo-Diaz A, et al. Contribution of HLA class II genes to end stage renal disease in mexican patients with type 2 diabetes mellitus. Hum Immunol 2000;61:1031–1038
(check this in PDF content)
37
Dyck R, Bohm C, Klomp H. Increased frequency of HLA A2/DR4 and A2/DR8 haplotypes in young saskatchewan aboriginal people with diabetic end-stage renal disease. Am J Nephrol 2003;23:178–185
(check this in PDF content)
38
Freedman BI, Spray BJ, Dunston GM, et al. HLA associations in end-stage renal disease due to membranous glomerulonephritis: HLA-DR3 associations with progressive renal injury. Southeastern Organ Procurement Foundation. Am J Kidney Dis 1994;23:797–802
(check this in PDF content)
39
Cogan MG. Medical Staff Conference. Tubulo-interstitial nephropathies – a pathophysiologic approach. West J Med 1980;132:134–140
(check this in PDF content)
40
Strutz F, Neilson EG. The role of lymphocytes in the progression of interstitial disease. Kidney Int 1994;45 [Suppl]: S106–S110
(check this in PDF content)
41
Braden GL, O‘Shea MH, Mulhern JG. Tubulointerstitial diseases. Am J Kidney Dis 2005;46:560–572
(check this in PDF content)
42
Norman JT, Fine LG. Progressive renal disease: fibroblasts, extracellular matrix, and integrins. Exp Nephrol 1999;7:167–177
(check this in PDF content)
43
Okoń K, Sułowicz W, Smoleński O, et al. Interstitial, tubular and vascular factors in progression of primary glomerulonephritis. Pol J Pathol 2007;58:73–78
(check this in PDF content)
44
Piscator M. Early detection of tubular dysfunction. Kidney Int 1991;34:S15–17
(check this in PDF content)
45
Blythe WB. Natural history of hypertension in renal parenchymal disease. Am J Kidney Dis 1985;5 (4):A50–56
(check this in PDF content)
46
Rosario RF, Wesson DE. Primary hypertension and nephropathy. Curr Opin Nephrol Hypertens 2006;15:130–134
(check this in PDF content)
47
Sugiura T, Wada A. Resistive index predicts renal prognosis in chronic kidney disease. Nephrol Dial Transplant 2009;24:2780–2785
(check this in PDF content)
48
Mujais S, Batlle DC. Functional correlates of tubulointerstitial damage. Semin Nephrol 1988;8:94–99
(check this in PDF content)
49
Eknoyan G, Qunibi WY, Grissom RT, et al. Renal papillary necrosis: an update. Medicine (Baltimore) 1982;61:55–73
(check this in PDF content)
50
Kelly CJ. Cellular immunity and the tubulointerstitium. Semin Nephrol 1999;19:182–187
(check this in PDF content)
51
Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996;7:2495–2508
(check this in PDF content)
52
Johnson DW, Saunders HJ, Baxter RC, et al. Paracrine stimulation of human renal fibroblasts by proximal tubule cells. Kidney Int 1998;54:747–757
(check this in PDF content)
53
Klahr S, Morrissey JJ. The role of growth factors, cytokines, and vasoactive compounds in obstructive nephropathy. Semin Nephrol 1998;18:622–632
(check this in PDF content)
54
Palmer BF. The renal tubule in the progression of chronic renal failure. J Investig Med 1997;45:346–361
(check this in PDF content)
55
Wardle EN. Modulatory proteins and processes in alliance with immune cells, mediators, and extracellular proteins in renal interstitial fibrosis. Ren Fail 1999;21:121–133
(check this in PDF content)
56
Nony PA, Schnellmann RG. Interactions between collagen IV and collagen-binding integrins in renal cell repair after sublethal injury. Mol Pharmacol 2001;60:1226–1234
(check this in PDF content)
57
Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004;15:1–12
(check this in PDF content)
58
Lopez-Novoa JM, Nieto MA. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med 2009;1:303–314
(check this in PDF content)
59
Iwano M, Plieth D, Danoff TM, et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002;110:341–350
(check this in PDF content)
60
Zeisberg M, Kalluri R. The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med 2004;82:175–181
(check this in PDF content)
61
Grande MT, López-Novoa JM. Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat Rev Nephrol 2009;5:319–328
(check this in PDF content)
62
Zeisberg M, Duffield JS. Resolved: EMT produces fibroblasts in the kidney. J Am Soc Nephrol 2010;21:1247–1253
(check this in PDF content)
63
Humphreys BD, Valerius MT, Kobayashi A, et al. Intrinsic epithelial cells repair the kidney after injury. Cell Stem Cell 2008;2:284–291
(check this in PDF content)
64
Humphreys BD, Lin SL, Kobayashi A, et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010;176:85–97
(check this in PDF content)
65
Becker GJ, Hewitson TD. The role of tubulointerstitial injury in chronic renal failure. Curr Opin Nephrol Hypertens 2000;9:133–138
(check this in PDF content)
66
Gibbs SR, Goins RA, Belvin EL, et al. Characterization of the collagen phenotype of rabbit proximal tubule cells in culture. Connect Tissue Res. 1999;40:173–188
(check this in PDF content)
67
Matsumoto Y, Ueda S, Yamagishi S, et al. Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. J Am Soc Nephrol 2007;18:1525–1533
(check this in PDF content)
68
Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis 2005;12:353–365
(check this in PDF content)
69
Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992;20:1–17
(check this in PDF content)
70
Lan HY, Nikolic-Paterson DJ, Mu W, et al. Local macrophage proliferation in the progression of glomerular and tubulointerstitial injury in rat anti-GBM glomerulonephritis. Kidney Int 1995;48:753–760
(check this in PDF content)
71
Nath KA. The tubulointerstitium in progressive renal disease. Kidney Int 1998;54:992–994.
(check this in PDF content)
72
Wang Y, Chen J, Chen L, et al. Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein. J Am Soc Nephrol 1997;8:1537–1545.]
(check this in PDF content)
73
Grandaliano G, Gesualdo L, Ranieri E, et al. Monocyte chemotactic peptide-1 expression in acute and chronic human nephritides: a pathogenetic role in interstitial monocytes recruitment. J Am Soc Nephrol 1996;7:906–913
(check this in PDF content)
74
Tesch GH, Maifert S, Schwarting A, et al. Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice. J Exp Med 1999;190:1813–1824
(check this in PDF content)
75
Rodemann HP, Muller GA. Abnormal growth and clonal proliferation of fibroblasts derived from kidneys with interstitial fibrosis. Proc Soc Exp Biol Med 1990;195:57–63
(check this in PDF content)
76
Rodemann HP, Muller GA. Characterization of human renal fibroblasts in health and disease: II. In vitro growth, differentiation, and collagen synthesis of fibroblasts from kidneys with interstitial fibrosis. Am J Kidney Dis 1991;17:684–686
(check this in PDF content)
77
El Nahas AM, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005;365:331–340
(check this in PDF content)
78
Chevalier RL. Obstructive nephropathy: towards biomarker discovery and gene therapy. Nat Clin Pract Nephrol 2006;2:157–168
(check this in PDF content)
79
Essawy M, Soylemezoglu O, Muchaneta-Kubara EC, et al. Myofibroblasts and the progression of diabetic nephropathy. Nephrol Dial Transplant 1997;12:43–50
(check this in PDF content)
80
Roberts IS, Burrows C, Shanks JH, et al. Interstitial myofibroblasts: predictors of progression in membranous nephropathy. J Clin Pathol 1997;50:123–127
(check this in PDF content)
81
Boukhalfa G, Desmouliere A, Rondeau E, et al. Relationship between alpha-smooth muscle actin expression and fibrotic changes in human kidney. Exp Nephrol 1996;4:241–247
(check this in PDF content)
82
Strutz F, Okada H, Lo CW, et al. Identification and characterization of a fibroblast marker: FSP1. J Cell Biol 1995;130:393–405
(check this in PDF content)
83
Schlondorff D. The role of chemokines in the initiation and progression of renal disease. Kidney Int 1995;49 [Suppl]: S44–S47
(check this in PDF content)
84
Bohle A, Mackensen-Haen S, Wehrmann M. Significance of postglomerular capillaries in the pathogenesis of chronic renal failure. Kidney Blood Press Res 1996;19:191–195
(check this in PDF content)
85
Mezzano SA, Aros CA, Droguett A, et al. Renal angiotensin II up-regulation and myofibroblast activation in human membranous nephropathy. Kidney Int 2003;86 [Suppl]: S39–S45
(check this in PDF content)
86
García-Sánchez O, López-Hernández FJ, Lopez-Novoa JM. An integrative view on the role of TGF-beta in the progressive tubular deletion associated with chronic kidney disease. Kidney Int 2010;77:950–955
(check this in PDF content)
87
Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol 2000;15:290–301
(check this in PDF content)
88
Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006;69:213–217
(check this in PDF content)
89
Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999;341:738–746
(check this in PDF content)
90
Eddy AA. Role of cellular infiltrates in response to proteinuria. Am J Kidney Dis 2001;37:S25–29
(check this in PDF content)
91
Nishida M, Fujinaka H, Matsusaka T, et al. Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis. J Clin Invest 2002;110:1859–1868
(check this in PDF content)
92
Goor H, Ding G, Kees-Folts D, et al. Macrophages and renal disease. Lab Invest 1994;71:456–464
(check this in PDF content)
93
Vleming LJ, Bruijn JA, van Es LA. The pathogenesis of progressive renal failure. Neth J Med 1999;54:114–128
(check this in PDF content)
94
Gharaee-Kermani M, Wiggins R, Wolber F, et al. Fibronectin is the major fibroblast chemoattractant in rabbit anti-glomerular basement membrane disease. Am J Pathol 1996;148:961–967
(check this in PDF content)
95
Eddy AA. Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J Am Soc Nephrol 1994;5:1273–1277
(check this in PDF content)
96
Vliet A, Baelde HJ, Vleming LJ, et al. Distribution of fibronectin isoforms in human renal disease. J Pathol 2001;193:256–262
(check this in PDF content)
97
Wells AF, Larsson E, Tengblad A, et al. The localization of hyaluronan in normal and rejected human kidneys. Transplantation 1990;50:240–243
(check this in PDF content)
98
Beck-Schimmer B, Oertli B, Pasch T, et al. Hyaluronan induces monocyte chemoattractant protein-1 expression in renal tubular epithelial cells. J Am Soc Nephrol 1998;9:2283–2290
(check this in PDF content)
99
Crawford SE, Stellmach V, Murphy-Ullrich JE,et al. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 1998;93:1159–1170
(check this in PDF content)
100
Hugo C, Shankland SJ, Pichler RH, et al. Thrombospondin 1 precedes and predicts the development of tubulointerstitial fibrosis in glomerular disease in the rat. Kidney Int 1998;53:302– 311
(check this in PDF content)
101
Diamond JR, Levinson M, Kreisberg R, et al. Increased expression of decorin in experimental hydronephrosis. Kidney Int 1997;51:1133–1139
(check this in PDF content)
102
Schaefer L, Hausser H, Altenburger M, et al. Decorin, biglycan and their endocytosis receptor in rat renal cortex. Kidney Int 1998;54:1529–1541
(check this in PDF content)
103
Gonzalez-Avila G, Vadillo-Ortega F, Perez-Tamayo R. Experimental diffuse interstitial renal fibrosis. A biochemical approach. Lab Invest 1988;59:245–252
(check this in PDF content)
104
Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Me 1994;331:1286–1292
(check this in PDF content)
105
Cheng J, Grande JP. Transforming growth factor-beta signal transduction and progressive renal disease. Exp Biol Med (Maywood) 2002;227:943–956
(check this in PDF content)
106
Roberts AB, McCune BK, Sporn MB. TGF-beta: regulation of extracellular matrix. Kidney Int 1992;41:557–559
(check this in PDF content)
107
Hultström M, Leh S, Skogstrand T,et al. Upregulation of tissue inhibitor of metalloproteases-1 (TIMP-1) and procollagenN-peptidase in hypertension-induced renal damage. Nephrol Dial Transplant 2008;23:896–903
(check this in PDF content)
108
Kim H, Oda T, Lopez-Guisa J, et al. TIMP-1 deficiency does not attenuate interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2000;12:736–748
(check this in PDF content)
109
Klahr S. Progression of chronic renal disease. Heart Dis 2001;3:205–209
(check this in PDF content)
110
García-Sánchez O, López-Hernández FJ, López-Novoa JM. An integrative view on the role of TGF-beta in the progressive tubular deletion associated with chronic kidney disease. Kidney Int 2010;77:950–955
(check this in PDF content)
111
Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006;17:17–25
(check this in PDF content)
112
Ortiz A, Lorz C, Egido J. The Fas ligand/Fas system in renal injury. Nephrol Dial Transplant 1999;14:1831–1834
(check this in PDF content)
113
Kelly DJ, Stein-Oakley A, Zhang Y, et al. Fas-induced apoptosis is a feature of progressive diabetic nephropathy in transgenic (mRen-2)27 rats: attenuation with renin-angiotensin blockade. Nephrology 2004;9:7–13
(check this in PDF content)
114
Lorz C, Ortiz A, Justo P, et al. Proapoptotic Fas ligand is expressed by normal kidney tubular epithelium and injured glomeruli. J Am Soc Nephrol 2000;11:1266–1277
(check this in PDF content)
115
Khan S, Koepke K, Jarad G, et al. Apoptosis and JNK activation are differentially regulated by Fas expression level in renal tubular epithelial cells. Kidney Int 2001;60:65–76
(check this in PDF content)
116
Jarad G, Wang B, Khan S, et al. Fas activation induces renal tubular epithelial cell beta 8 integrin expression and function in the absence of apoptosis. J Biol Chem 2002;277:47826–47833
(check this in PDF content)
117
Santiago B, Galindo M, Palao G,et al. Intracellular regulation of Fas-induced apoptosis in human fibroblasts by extracellular factors and cycloheximide. J Immunol 2004;172:560– 566
(check this in PDF content)
118
Miyajima A, Chen J, Lawrence C, et al. Antibody to transforming growth factor-beta ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney Int 2000;58:2301–2313
(check this in PDF content)
119
Kelly DJ, Cox AJ, Tolcos M, et al. Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats. Kidney Int 2002;61:31–39
(check this in PDF content)
120
Bhaskaran M, Reddy K, Radhakrishanan N, et al. Angiotensin II induces apoptosis in renal proximal tubular cells. Am J Physiol Ren Physiol 2003;284:F955–965
(check this in PDF content)
121
Ortiz-Arduan A, Danoff TM, Kalluri R, et al. Regulation of Fas and Fas ligand expression in cultured murine renal cells and in the kidney during endotoxemia. Am J Physiol 1996;271:F1193– 1201
(check this in PDF content)
122
Schelling JR, Nkemere N, Kopp JB, et al. Fas-dependent fratricidal apoptosis is a mechanism of tubular epithelial cell deletion in chronic renal failure. Lab Invest 1998;78:813–824
(check this in PDF content)
123
Khan S, Cleveland RP, Koch CJ, et al. Hypoxia induces renal tubular epithelial cell apoptosis in chronic renal disease. Lab Invest 1999;79:1089–1099
(check this in PDF content)
124
Koesters R, Kaissling B, Lehir M,et al. Tubular overexpression of transforming growth factor-beta1 induces autophagy and fibrosis but not mesenchymal transition of renal epithelial cells. Am J Pathol 2010;177:632–643
(check this in PDF content)
125
Sanz AB, Santamaria B, Ruiz Ortega M, et al. Mechanisms of renal apoptosis in health and disease. J Am Soc Nephrol 2008;19:1634–1642
(check this in PDF content)
126
Ichikawi I, Harris RC. Angiotensin actions in the kidney: renewed insight into the old hormone. Kidney Int 1991;40:583–596
(check this in PDF content)
127
Wang CZ, Hsu YM, Tang MJ. Function of discoidin domain receptor I in HGF-induced branching tubulogenesis of MDCK cells in collagen gel. J Cell Physiol 2005;203:295–304
(check this in PDF content)
128
Hughes J. Life and death in the kidney: prospects for future therapy. Nephrol Dial Transplant 2001;16:879–882
(check this in PDF content)
129
Broe ME. Apoptosis in acute renal failure. Nephrol Dial Transplant 2001;16 [Suppl 6]: 23–26
(check this in PDF content)
130
Nilakantan V, Maenpaa C, Jia G, et al. 20-HETE-mediated cytotoxicity and apoptosis in ischemic kidney epithelial cells. Am J Physiol Renal Physiol 2008;294:F562–570
(check this in PDF content)
131
Orphanides C, Fine LG, Norman JT. Hypoxia stimulates proximal tubular cell matrix production via a TGF-beta1independent mechanism. Kidney Int 1997;52:637–647
(check this in PDF content)
132
Haase VH. Pathophysiological Consequences of HIF Activation: HIF as a modulator of fibrosis. Ann N Y Acad Sci 2009;1177:57–65
(check this in PDF content)
133
López-Novoa JM, Nieto MA. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med 2009;1:303–314
(check this in PDF content)
134
Serón D, Alexopoulos E, Raftery MJ, et al. Number of interstitial capillary cross-sections assessed by monoclonal antibodies: relation to interstitial damage. Nephrol Dial Transplant 1990;5:889–893
(check this in PDF content)
135
Couser WG. Pathogenesis of glomerular damage in glomerulonephritis. Nephrol Dial Transplant 1998;13:10–15
(check this in PDF content)
136
Isaka Y, Akagi Y, Ando Y, et al. Cytokines and glomerulosclerosis. Nephrol Dial Transplant 1999;14:30–32
(check this in PDF content)
137
Nangaku M, Couser WG. Mechanisms of immunedeposit formation and the mediation of immune renal injury. Clin Exp Nephrol 2005;9:183–191
(check this in PDF content)
138
Couser WG. Complement inhibitors and glomerulonephritis: are we there yet? J Am Soc Nephrol 2003;14:815–818
(check this in PDF content)
139
Cunard R, Jelly CJ. Immune-mediated renal disease. J Allergy Clin Immunol 2003;111:S637–644
(check this in PDF content)
140
Shimizu A, Masuda Y, Kitamura H, et al. Recovery of damaged glomerular capillary network with endothelial cell apoptosis in experimental proliferative glomerulonephritis. Nephron 1998;79:206–214
(check this in PDF content)
141
U.S. Renal Data System, USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2005
(check this in PDF content)
142
López-Hernández FJ, López-Novoa JM. The lord of the ring: Mandatory role of the kidney in drug therapy of hypertension. Pharmacol Ther 2006;111:53–80
(check this in PDF content)
143
López-Novoa JM, Martínez-Salgado C, Rodríguez-Peña AB, et al. Common pathophysiological mechanisms of chronic kidney disease: Therapeutic perspectives. Pharmacol Ther 2010;128:61–81
(check this in PDF content)
144
Tervaert TW, Mooyaart AL, Amann K, et al. Renal Pathology Society. Pathologic Classification of Diabetic Nephropathy. J Am Soc Nephrol 2010;21:556–563
(check this in PDF content)
145
Wesson LG. Physical factors and glomerulosclerosis. Cause or coincidence? Nephron 1998;78:125–130
(check this in PDF content)
146
Wiggins RC. The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int 2007;71:1205–1214
(check this in PDF content)
147
Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 2008;4:39–45
(check this in PDF content)
148
Moreno JA, Sanchez-Niño MD, Sanz AB, et al. A slit in podocyte death. Curr Med Chem 2008;15:1645–1654
(check this in PDF content)
149
Kang YS, Li Y, Dai C, et al. Inhibition of integrin-linked kinase blocks podocyte epithelial-mesenchymal transition and ameliorates proteinuria. Kidney Int 2010;78:363–373
(check this in PDF content)
150
Kriz W, LeHir M. Pathways to nephron loss starting from glomerular diseases-insights from animal models. Kidney Int 2005;67:404–419
(check this in PDF content)
151
Harris RC, Akai Y, Yasuda T, et al. The role of physical forces in alterations of mesangial cell function. Kidney Int 1994;45 [Suppl]: S17–S21
(check this in PDF content)
152
Funabiki K, Horikoshi S, Tomino Y, et al. Immunohistochemical analysis of extracellular components in the glomerular sclerosis of patients with glomerulonephritis. Clin Nephrol 1990;34:239–246
(check this in PDF content)
153
Makino H, Kashihara N, Sugiyama H, et al. Role of apoptosis in the progression of glomerulosclerosis. Contrib Nephrol 1996;118:41–47
(check this in PDF content)
154
Kurogi Y. Mesangial cell proliferation inhibitors for the treatment of proliferative glomerular disease. Med Res Rev 2003;23:15–31
(check this in PDF content)
155
Morel-Maroger Striker L, Killen PD, Chi E, et al. The composition of glomerulosclerosis. I. Studies in focal sclerosis, crescentic glomerulonephritis, and membranoproliferative glomerulonephritis. Lab Invest 1984;51:181–192
(check this in PDF content)
156
Floege J, Johnson RJ, Couser WG. Mesangial cells in the pathogenesis of progressive glomerular disease in animal models. Clin Investig 1992;70:857–864
(check this in PDF content)
157
Massy ZA, Guijarro C, O’Donnell MP, et al. The central role of nuclear factor-kappa B in mesangial cell activation. Kidney Int 1999;71 [Suppl]: S76–S79
(check this in PDF content)
158
Johnson RJ, Alpers CE, Yoshimura A, et al. Renal injury from angiotensin II-mediated hypertension. Hypertension 1992;19:464–474
(check this in PDF content)
159
Ardaillou R, Chansel D, Chatziantoniou C, et al. Mesangial AT1 receptors: expression, signaling, and regulation. J Am Soc Nephrol 1999;10:S40–46
(check this in PDF content)
160
Kagami S, Kondo S, Löster K, et al. Alpha1beta1 integrin-mediated collagen matrix remodeling by rat mesangial cells is differentially regulated by transforming growth factorbeta and platelet-derived growth factor-BB. J Am Soc Nephrol 1999;10:779–789
(check this in PDF content)
161
Haberstroh U, Zahner G, Disser M, et al. TGF-beta stimulates rat mesangial cell proliferation in culture: role of PDGF beta-receptor expression. Am J Physiol 1993;264:F199–205
(check this in PDF content)
162
Bessho K, Mizuno S, Matsumoto K, et al. Counteractive effects of HGF on PDGF-induced mesangial cell proliferation in a rat model of glomerulonephritis. Am J Physiol Renal Physiol 2003;284:F1171–180
(check this in PDF content)
163
Gomez-Garre D, Ruiz-Ortega M, Ortego M, et al. Effects and interactions of endothelin-1 and angiotensin II on matrix protein expression and synthesis and mesangial cell growth. Hypertension 1996;27:885–892
(check this in PDF content)
164
Hahn S, Krieg RJ Jr, Hisano S, et al. Vitamin E suppresses oxidative stress and glomerulosclerosis in rat remnant kidney. Pediatr Nephrol 1999;13:195–198
(check this in PDF content)
165
Jaimes EA, Galceran JM, Raij L. Angiotensin II induces superoxide anion production by mesangial cells. Kidney Int 1998;54:775–784
(check this in PDF content)
166
Couser WG. Pathogenesis of glomerulonephritis. Kidney Int 1993;42 [Suppl]: S19–S26
(check this in PDF content)
167
Grande MT, Perez-Barriocanal F, Lopez-Novoa JM. Role of inflammation in túbulo-interstitial damage associated to obstructive nephropathy. J Inflamm (Lond) 2010;7:19
(check this in PDF content)
168
Johnson RJ, Iida H, Alpers CE, et al. Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis. Alpha-smooth muscle actin is a marker of mesangial cell proliferation. J Clin Invest 1991;87:847–858
(check this in PDF content)
169
Alpers CE, Hudkins KL, Gown AM, et al. Enhanced expression of ”muscle-specific” actin in glomerulonephritis. Kidney Int 1992;41:1134–1142
(check this in PDF content)
170
Stokes MB, Holler S, Cui Y, et al. Expression of decorin, biglycan, and collagen type I in human renal fibrosing disease. Kidney Int 2000;57:487–498
(check this in PDF content)
171
Couser WG, Johnson RJ. Mechanisms of progressive renal disease in glomerulonephritis. Am J Kidney Dis 1994;23:193– 198
(check this in PDF content)
172
Justo P, Sanz AB, Sanchez-Niño MD, et al. Cytokine cooperation in renal tubular cell injury: the role of TWEAK. Kidney Int 2006;70:1750–1758
(check this in PDF content)
173
Sanchez-Niño MD, Benito-Martin A, Gonçalves S, et al. TNF superfamily: a growing saga of kidney injury modulators. Mediators Inflamm;2010. pii: 182958. Epub 2010 Oct 4
(check this in PDF content)
174
Strutz F, Neilson EG. New insights into mechanisms of fibrosis in immune renal injury. Springer Semin Immunopathol 2003;24:459–476
(check this in PDF content)
175
Border WA, Noble NA. TGF-beta in kidney fibrosis: a target for gene therapy. Kidney Int 1997;51:1388–1396
(check this in PDF content)
176
Tamaki K, Okuda S. Role of TGF-beta in the progression of renal fibrosis. Contrib Nephrol 2003;139:44–65
(check this in PDF content)
177
Chiarugi A. «Simple but not simpler»: toward a unified picture of energy requirements in cell death. FASEB J 2005;19:1783–1788
(check this in PDF content)
178
Rusterholz C, Gupta AK, Huppertz B, et al. Soluble factors released by placental villous tissue: Interleukin-1 is a potential mediator of endothelial dysfunction. Am J Obstet Gynecol 2005;192:618–624
(check this in PDF content)
179
Gao X, Zhang H, Belmadani S,et al. Role of TNF-alphainduced reactive oxygen species in endothelial dysfunction during reperfusion injury. Am J Physiol Heart Circ Physiol 2008;295:H2242–2249
(check this in PDF content)
180
Zhang C, Wu J, Xu X, et al. Direct relationship between levels of TNF-alpha expression and endothelial dysfunction in reperfusion injury. Basic Res Cardiol 2010;105:453–464
(check this in PDF content)
181
Camussi G, Turello E, Tetta C, et al. Tumor necrosis factor induces contraction of mesangial cells and alters their cytoskeletons. Kidney Int 1990;38:795–802
(check this in PDF content)
182
López-Farré A, Gómez-Garre D, Bernabeu F, Renal effects and mesangial cell contraction induced by endothelin are mediated by PAF. Kidney Int 1991;39:624–630
(check this in PDF content)
183
Bussolati B, Mariano F, Biancone L,et al. Interleukin-12 is synthesized by mesangial cells and stimulates platelet-activating factor synthesis, cytoskeletal reorganization, and cell shape change. Am J Pathol 1999;154:623–632
(check this in PDF content)
184
López-Novoa JM. Potential role of platelet activating factor in acute renal failure. Kidney Int 1999;55:1672–1682
(check this in PDF content)
185
Molitoris BA, Sutton TA. Endothelial injury and dysfunction: role in the extension phase of acute renal failure. Kidney Int 2004;66:496–499
(check this in PDF content)
186
Bonventre JV. Pathophysiology of AKI: injury and normal and abnormal repair. Contrib Nephrol 2010;165:9–17. full_text
(check this in PDF content)
187
Rodriguez-Barbero A, L’Azou B, Cambar J,et al. Potential use of isolated glomeruli and cultured mesangial cells as in vitro models to assess nephrotoxicity. Cell Biol Toxicol 2000;16:145–153
(check this in PDF content)
188
Wolf G, Ziyadeh FN. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol 2007;106:26–31
(check this in PDF content)
189
Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 2008;4:39–45
(check this in PDF content)
190
Smeets B, Dijkman H, Wetzels J, et al. Lessons from studies on focal segmental glomerulosclerosis: an important role for parietal epithelial cells? J Pathol 2006;210:263–272
(check this in PDF content)
191
Asano T, Niimura F, Pastan I, et al. Permanent genetic tagging of podocytes: fate of injured podocytes in a mouse model of glomerular sclerosis. J Am Soc Nephrol 2005;16:2257–2262
(check this in PDF content)
192
Pätäri-Sampo A, Ihalmo P, Holthöfer H. Molecular basis of the glomerular filtration: nephrin and the emerging protein complex at the podocyte slit diaphragm. Ann Med 2006;38:483–492
(check this in PDF content)
193
Barisoni L, Mundel P. Podocyte biology and the emerging understanding of podocyte diseases. Am J Nephrol. 2003;23:353–360
(check this in PDF content)
194
Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998;339:1448–1456
(check this in PDF content)
195
Morioka Y, Koike H, Ikezumi Y, et al. Podocyte injuries exacerbate mesangial proliferative glomerulonephritis. Kidney Int 2001;60:2192–2204
(check this in PDF content)
196
Sawai K, Mori K, Mukoyama M, et al. Angiogenic protein Cyr61 is expressed by podocytes in anti-Thy-1 glomerulonephritis. J Am Soc Nephrol 2003;14:1154–1163
(check this in PDF content)
197
Chen S, Kasama Y, Lee JS, et al. Podocyte-derived vascular endothelial growth factor mediates the stimulation of alpha3(IV) collagen production by transforming growth factorbeta1 in mouse podocytes. Diabetes 2004;53:2939–2949
(check this in PDF content)
198
Kang YS, Park YG, Kim BK, et al. Angiotensin II stimulates the synthesis of vascular endothelial growth factor through the p38 mitogen activated protein kinase pathway in cultured mouse podocytes. J Mol Endocrinol 2006;36:377–388
(check this in PDF content)
199
Wang L, Kwak JH, Kim SI, et al. Transforming growth factor-beta1 stimulates vascular endothelial growth factor 164 via mitogen-activated protein kinase kinase 3-p38alpha and p38delta mitogen-activated protein kinase-dependent pathway in murine mesangial cells. J Biol Chem 2004;279:33213–33219
(check this in PDF content)
200
Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases: Is the podocyte the culprit? Kidney Int 1998;54:687–697
(check this in PDF content)
201
Pagtalunan ME, Miller PL, Jumping-Eagle S, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997;99:342–348.
(check this in PDF content)
202
Lemley KV, Lafayette RA, Safai M, et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int 2002;61:1475– 1485
(check this in PDF content)
203
U.S. Renal Data System, USRDS 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2002
(check this in PDF content)
204
Olin JW. Atherosclerotic renal artery disease. Cardiol Clin. 2002;20:547–562.
(check this in PDF content)
205
Mast Q, Beutler JJ. The prevalence of atherosclerotic renal artery stenosis in risk groups: a systematic literature review. J Hypertens 2009;27:1333–1340
(check this in PDF content)
206
Rihal CS, Textor SC, Breen JF, et al. Incidental renal artery stenosis among a prospective cohort of hypertensive patients undergoing coronary angiography. Mayo Clin Proc 2002;77:309–316
(check this in PDF content)
207
Garovic VD, Textor SC. Renovascular hypertension and ischemic nephropathy. Circulation 2005;112:1362–1374
(check this in PDF content)
208
Textor SC. Ischemic nephropathy: where are we now? J Am Soc Nephrol 2004;15:1974–1982
(check this in PDF content)
209
Chade AR, Rodriguez-Porcel M, Grande JP, et al. Mechanisms of renal structural alterations in combined hypercholesterolemia and renal artery stenosis. Arterioscler Thromb Vasc Biol 2003;23:1295–1301
(check this in PDF content)
210
Chade AR, Lerman A, Lerman LO. Kidney in early atherosclerosis. Hypertension 2005;45:1042–1049
(check this in PDF content)
211
Harrison D, Griendling KK, Landmesser U, et al. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003;91:7A–11A
(check this in PDF content)
212
Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin IImediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996;97:1916–1923
(check this in PDF content)
213
Reckelhoff JF, Romero JC. Role of oxidative stress in angiotensin-induced hypertension. Am J Physiol Regul Integr Comp Physiol 2003;284:R893–R912
(check this in PDF content)
214
Chade AR, Krier JD, Rodriguez-Porcel M, et al. Comparison of acute and chronic antioxidant interventions in experimental renovascular disease. Am J Physiol Renal Physiol 2004;286:F1079–F1086
(check this in PDF content)
215
Oliveira-Sales EB, Dugaich AP, Carillo BA, et al. Oxidative stress contributes to renovascular hypertension. Am J Hypertens 2008;21:98–104
(check this in PDF content)
216
Schnackenberg CG. Physiological and pathophysiological roles of oxygen radicals in the renal microvasculature. Am J Physiol Regul Integr Comp Physiol 2002;282:R335–R342
(check this in PDF content)
217
Textor SC, Novick AC, Tarazi RC, et al. Critical perfusion pressure for renal function in patients with bilateral atherosclerotic renal vascular disease. Ann Intern Med 1985;102:308–314
(check this in PDF content)
218
Epstein FH. Oxygen and renal metabolism. Kidney Int 1997;51:381–385
(check this in PDF content)
219
Spence JD. Treatment options for renovascular hypertension. Expert Opin Pharmacother 2002;3:411–416
(check this in PDF content)
220
Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med 2001;344:431–442
(check this in PDF content)
221
Iliescu R, Fernandez SR, Kelsen S, et al. Role of renal microcirculation in experimental renovascular disease. Nephrol Dial Transplant 2010;25:1079–1087
(check this in PDF content)
222
Haase VH. Pathophysiological Consequences of HIF Activation: HIF as a modulator of fibrosis. Ann N Y Acad Sci 2009;1177:57–65
(check this in PDF content)
223
Moran K, Mulhall J, Kelly D, et al. Morphological changes and alterations in regional intrarenal blood flow induced by graded renal ischemia. J Urol 1992;148:463–466
(check this in PDF content)
224
Jeong JI, Lee YW, Kim YK. Chemical hypoxia-induced cell death in human glioma cells: role of reactive oxygen species, ATP depletion, mitochondrial damage and Ca2+. Neurochem Res 2003;28:1201–1211
(check this in PDF content)
225
Seppet E, Gruno M, Peetsalu A, et al. Mitochondria and energetic depression in cell pathophysiology. Int J Mol Sci 2009;10:2252–2303
(check this in PDF content)
226
Sato T, Oku H, Tsuruma K, et al. Effect of hypoxia on susceptibility of RGC-5 cells to nitric oxide. Invest Ophthalmol Vis Sci 2010;51:2575–2486
(check this in PDF content)
227
Kiang JG, Tsen KT. Biology of hypoxia. Chin J Physiol 2006;49:223–233
(check this in PDF content)
228
Voiculescu A, Grabensee B, Jung G, et al. Renovascular disease: a review of diagnostic and therapeutic procedures. Minerva Urol Nefrol 2006;58:127–149
(check this in PDF content)
229
Chade AR, Rodriguez-Porcel M, Grande JP, et al. Mechanisms of renal structural alterations in combined hypercholesterolemia and renal artery stenosis. Arterioscler Thromb Vasc Biol 2003;23:1295–1230
(check this in PDF content)
230
Gallego B, Arevalo MA, Flores O, et al. Renal fibrosis in diabetic and aortic-constricted hypertensive rats. Am J Physiol Regul Integr Comp Physiol 2001;280:R1823–R1829
(check this in PDF content)
231
Gallego B, Arevalo, Flores O,et al. Effect of chronic and progressive aortic constriction on renal function and structure in rats. Can J Physiol Pharmacol 2001;79:601–607
(check this in PDF content)
232
Textor SC. Pathophysiology of renovascular hypertension. Urol Clin North Am 1984;11:373–381
(check this in PDF content)
233
Navar LG, Von Thun AM, Zou L, et al. Enhancement of intrarenal angiotensin II levels in 2 kidney 1 clip and angiotensin II induced hypertension. Blood Press 1995;2 [Suppl]: 88–92
(check this in PDF content)
234
Zimmerman MC, Lazartigues E, Sharma RV, et al. Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circ Res 2004;95:210–216
(check this in PDF content)
235
Wolf G, Schneider A, Wenzel U, et al. Regulation of glomerular TGF-beta expression in the contralateral kidney of two-kidney, one-clip hypertensive rats. J Am Soc Nephrol 1998;9:763–772
(check this in PDF content)
236
Bohle A, Muller GA, Wehrmann M,et al. Pathogenesis of chronic renal failure in the primary glomerulopathies, renal vasculopathies, and chronic interstitial nephritides. Kidney Int 1996;54 [Suppl]: S2–S9
(check this in PDF content)
237
Komlosi P, Bell PD, Zhang ZR. Tubuloglomerular feedback mechanisms in nephron segments beyond the macula densa. Curr Opin Nephrol Hypertens 2009;18:57–62
(check this in PDF content)
238
Kriz W, Hosser H, Hahnel B, et al. From segmental glomerulosclerosis to total nephron degeneration and interstitial fibrosis: a histopathological study in rat models and human glomerulopathies. Nephrol Dial Transplant 1998;13:2781–2798
(check this in PDF content)
239
Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol 2006;17:2974–2984
(check this in PDF content)
240
Baines RJ, Brunskill NJ. Tubular toxicity of proteinuria. Nat Rev Nephrol 2011 Mar;7(3):177-180
(check this in PDF content)
241
Buelli S, Abbate M, Morigi M, et al. Protein load impairs factor H binding promoting complement-dependent dysfunction of proximal tubular cells. Kidney Int 2009;75:1050–1059
(check this in PDF content)
242
Macconi D, Chiabrando C, Schiarea S, et al. Proteasomal processing of albumin by renal dendritic cells generates antigenic peptides. J Am Soc Nephrol 2009;20:123–130.
(check this in PDF content)
243
Lapsley M, Flynn FV, Sansom PA. Beta 2-glycoprotein-1 (apolipoprotein H) excretion and renal tubular malfunction in diabetic patients without clinical proteinuria. J Clin Pathol 1993;46:465–469
(check this in PDF content)
244
Hong CY, Hughes K, Chia KS, et al. Urinary alpha1microglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in Singapore. Diabetes Care 2003;26:338–342
(check this in PDF content)
245
Thomas MC, Burns WC, Cooper ME. Tubular changes in early diabetic nephropathy. Adv Chronic Kidney Dis 2005;12:177– 186
(check this in PDF content)
246
Thomson SC, Vallon V, Blantz RC. Kidney function in early diabetes: the tubular hypothesis of glomerular filtration. Am J Physiol Renal Physiol 2006;286:F8–F15
(check this in PDF content)
247
Singh DK, Winocour P, Farrington K. Mechanisms of disease: the hypoxic tubular hypothesis of diabetic nephropathy. Nat Clin Pract Nephrol 2008;4:216–226
(check this in PDF content)
248
Koomans HA, Blankestijn PJ, Joles JA. Sympathetic hyperactivity in chronic renal failure: A wake-up call. J Am Soc Nephrol 2004;15:524–537
(check this in PDF content)
249
Perico N, Benigni A, Remuzzi G. Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection. Nat Rev Drug Discov 2008;7:936–953
(check this in PDF content)
250
Zeisberg M, Kalluri R. Reversal of experimental renal fibrosis by BMP7 provides insights into novel therapeutic strategies for chronic kidney disease. Pediatr Nephrol 2008;23:1395–1398
(check this in PDF content)
251
Wang S, Chen Q, Simon TC, et al. Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int 2003;63:2037–2049
(check this in PDF content)
252
Leask A, Abraham DJ. TGF-β signaling and the fibrotic response. FASEB J 2004;18 (7):816–827
(check this in PDF content)
253
Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 2009;19:156–172
(check this in PDF content)
254
Wang SN, Lapage J, Hirschberg R. Glomerular ultrafiltration and apical tubular action of IGF-I, TGF-beta, and HGF in nephrotic syndrome. Kidney Int 1999;56:1247–1251
(check this in PDF content)
255
Duncan MR, Frazier KS, Abramson S,et al. Connective tissue growth factor mediates transforming growth factor betainduced collagen synthesis: downregulation by cAMP. FASEB J 1999;13:1774–1786
(check this in PDF content)
256
Okada H, Danoff TM, Kalluri R,et al. Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol 1997;273:F563–574
(check this in PDF content)
257
Strutz F, Zeisberg M, Ziyadeh FN, et al. Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int 2002;61:1714–1728
(check this in PDF content)
258
Kriz W, Hahnel B, Rosener S, et al. Long-term treatment of rats with FGF-2 results in focal segmental glomerulosclerosis. Kidney Int 1995;48:1435–1450
(check this in PDF content)
259
Phillips AO, Topley N, Morrisey K, et al. Basic fibroblast growth factor stimulates the release of preformed transforming growth factor beta 1 from human proximal tubular cells in the absence of de novo gene transcription or mRNA translation. Lab Invest 1997;76:591–600
(check this in PDF content)
260
Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004;15:255–273
(check this in PDF content)
261
Weston BS, Wahab NA, Mason RM. CTGF mediates TGF-beta-induced fibronectin matrix deposition by upregulating active alpha5beta1 integrin in human mesangial cells. J Am Soc Nephrol 2003;14:601–610
(check this in PDF content)
262
Wahab NA, Weston BS, Mason RM. Modulation of the TGFbeta/Smad signaling pathway in mesangial cells by CTGF/ CCN2. Exp Cell Res 2005;307:305–314
(check this in PDF content)
263
Francki A, Bradshaw AD, Bassuk JA, et al. SPARC regulates the expression of collagen type I and transforming growth factor-beta1 in mesangial cells. J Biol Chem 1999; 274:32145–32152
(check this in PDF content)
264
Okada H, Danoff TM, Kalluri R, et al. Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol 1997;273:F563–F574
(check this in PDF content)
265
Brown NJ, Vaughan DE, Fogo AB. Aldosterone and PAI-1: implications for renal injury. J Nephrol 2002;15:230–235
(check this in PDF content)
266
Biancone L, David S, Della Pietra V, et al. Alternative pathway activation of complement by cultured human proximal tubular epithelial cells. Kidney Int 1994;45:451–460
(check this in PDF content)
267
Tang S, Sheerin NS, Zhou W, et al. Apical proteins stimulate complement synthesis by cultured human proximal tubular epithelial cells. J Am Soc Nephrol 1999;10:69–76
(check this in PDF content)
268
Nangaku M, Pippin J, Couser WG. Complement membrane attack complex (C5b-9) mediates interstitial disease in experimental nephrotic syndrome. J Am Soc Nephrol 1999;10:2323–2331
(check this in PDF content)
269
Nomura A, Morita Y, Maruyama S, et al. Role of complement in acute tubulointerstitial injury of rats with aminonucleoside nephrosis. Am J Pathol 1997;151:539–547
(check this in PDF content)
270
Hill PA, Lan HY, Nikolic-Paterson DJ, et al. ICAM-1 directs migration and localization of interstitial leukocytes in experimental glomerulonephritis. Kidney Int 1994;45:32–42
(check this in PDF content)
271
Ricardo SD, Levinson ME, DeJoseph MR, et al. Expression of adhesion molecules in rat renal cortex during experimental hydronephrosis. Kidney Int 1996;50:2002–2010
(check this in PDF content)
272
Ophascharoensuk V, Giachelli CM, Gordon K, et al. Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int 1999;56:571–580
(check this in PDF content)
273
Zoja C, Morigi M, Figliuzzi M, et al. Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am J Kidney Dis 1995;26:934–941
(check this in PDF content)
274
Largo R, Gómez-Garre D, Soto K, et al. Angiotensinconverting enzyme is upregulated in the proximal tubules of rats with intense proteinuria. Hypertension 1999;33:732–739
(check this in PDF content)
275
Benigni A, Remuzzi G. How renal cytokines and growth factors contribute to renal disease progression. Am J Kidney Dis 2001;37 [1 Suppl 2]: S21–S24
(check this in PDF content)
276
Abe K, Li K, Sacks SH, et al. The membrane attack complex, C5b-9, up regulates collagen gene expression in renal tubular epithelial cells. Clin Exp Immunol 2004;136:60–66
(check this in PDF content)
277
Justo P, Sanz AB, Sanchez-Niño MD, et al. Cytokine cooperation in renal tubular cell injury: the role of TWEAK. Kidney Int 2006;70:1750–1758
(check this in PDF content)
278
Wolfs TG, Buurman WA, van Schadewijk A, et al. In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells: IFN-gamma and TNF-alpha mediated up-regulation during inflammation. J Immunol 2002;168:1286–1293
(check this in PDF content)
279
Guo G, Morrissey J, McCracken R, et al. Contributions of angiotensin II and tumor necrosis factor-alpha to the development of renal fibrosis. Am J Physiol Renal Physiol 2001;280:F777–F785
(check this in PDF content)
280
Longaretti L, Benigni A. Endothelin receptor selectivity in chronic renal failure. Eur J Clin Invest 2009;39 [Suppl 2]:32–37
(check this in PDF content)
281
Kagami S, Border WA, Miller DE, et al. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431–2437
(check this in PDF content)
282
Gilbert RE, Wu LL, Kelly DJ, et al. Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis. Am J Pathol 1999;155:429–440
(check this in PDF content)
283
Yang J, Dai C, Liu Y. Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice. J Am Soc Nephrol 2002;13:2464–2477
(check this in PDF content)
284
Ursula C, Brewster MD, Mark A,et al. The reninangiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 2004;116:263–272
(check this in PDF content)
285
Zeisberg M, Bonner G, Maeshima Y, et al. Renal fibrosis: collagen composition and assembly regulates epithelialmesenchymal transdifferentiation. Am J Pathol 2001;159:1313– 1321
(check this in PDF content)
286
Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 2001;159:1465–1475
(check this in PDF content)
287
Liu Y. Hepatocyte growth factor promotes renal epithelial cell survival by dual mechanisms. Am J Physiol 1999;277:F624– F633
(check this in PDF content)
288
Yang J, Liu Y. Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. J Am Soc Nephrol 2002;13:96–107
(check this in PDF content)
289
Dworkin LD, Gong R, Tolbert E, et al. Hepatocyte growth factor ameliorates progression of interstitial fibrosis in rats with established renal injury. Kidney Int 2004;65:409–419
(check this in PDF content)
290
Esposito C, Parrilla B, De Mauri A,et al. Hepatocyte growth factor (HGF) modulates matrix turnover in human glomeruli. Kidney Int 2005;67:2143–2150
(check this in PDF content)
291
Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol 2008;48:463–493 Поступила в редакцию 11.02.2013 г. Принята в печать 27.03.2013 г.
(check this in PDF content)